GLP-1 Collective

Policy Tracker · Patient Lens · July 19, 2026

Ten patients now say Novo Nordisk built its own prices unfairly

Their lawsuits could force the company to explain how it set Ozempic and Wegovy costs in the first place.

Nothing new was filed in the last day. These are the 8 most recent developments affecting GLP-1 access that this tracker has not covered yet, across 1 category. Each entry links to the full record.

## Courts and enforcement

**[Lawsuit challenges Novo Nordisk's GLP-1 pricing practices](/lawsuits/cl-73534601)**.

**[Mottola sues Novo Nordisk over pricing and marketing](/lawsuits/cl-73534111)**.

**[Patient sues Novo Nordisk over high GLP-1 drug prices and patent](/lawsuits/cl-73532011)**.

**[Patients sue Novo Nordisk over Ozempic and Wegovy pricing](/lawsuits/cl-73531706)**.

**[Novo Nordisk sued over GLP-1 marketing and pricing claims](/lawsuits/cl-73536818)**.

**[Luellen v. Novo Nordisk, what's at stake](/lawsuits/cl-73527004)**.

**[Novo Nordisk sued over GLP-1 pricing and marketing](/lawsuits/cl-73528821)**.

**[Parker sues Novo Nordisk over GLP-1 drug practices](/lawsuits/cl-73528036)**.

3 further items in this category were tracked today and are listed on the site.

By Amanda Bonello

Originally published by Patient Lens on GLP-1 Laws, operated by GLP-1 Studio LLC — a for-profit company founded by the Collective's Executive Director. Republished here in full, with permission, at no cost. The Collective pays nothing for it and receives no payment for publishing it. How this works.